---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015398"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:04:45.995546+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps

## Summary
- Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.
- R&D expenses surged to $21.6M from $4.6M on clinical trial and manufacturing costs.
- Cash and equivalents $143.6M; expects funding into Q2 2023.
- Phase 3 Lumeos trial for XLRP screening; AQUAx xerostomia Phase 1 enrollment to complete Q4 2021.
- IND planned for AAV-GAD in Parkinson's and Phase 3 pivotal trial for AAV-RPE65 in early 2022.

## SEC filing metadata
- accession: 0001558370-21-015398
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/0001558370-21-015398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/mgtx-20211110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015398
- JSON: https://secwatch.observer/filing/0001558370-21-015398.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.